42
Participants
Start Date
May 31, 2011
Primary Completion Date
November 30, 2016
Study Completion Date
December 31, 2016
Nebivolol
5 mg tablet to be taken by mouth once per day for 12 weeks
Metoprolol
100 mg tablet to be taken by mouth once per day for 12 weeks
Placebo
gelatin capsule to be taken by mouth once per day for 12 weeks
Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)
The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
FBF response to Acetylcholine
The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
FBF response to Sodium Nitroprusside
The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
FBF response to BQ-123+BQ-788+ACh
The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
UC-Boulder Clinical and Translational Research Center, Boulder
Collaborators (1)
Forest Laboratories
INDUSTRY
University of Colorado, Boulder
OTHER